Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors from the central anxious system, conolidine modulates alternate molecular targets. A Science Advances research observed that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://cates311sqf1.wikirecognition.com/user